Hiroshi Kobe

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 89 citations

Medicine, Oncology, Pharmacology +12

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer

Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki et al. · CHEST Journal · 2022 · 40 citations

Medicine, Oncology, Pharmacology +12

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

Mihoko Imaji, Daichi Fujimoto, Yuki Sato et al. · European Journal of Cancer · 2022 · 22 citations

Pharmacy, Pharmacotherapy, Pulmonology +6

Bioremediation of Organic matter loaded on the sediment in outdoor pools with a polychaete, <i>Capitella</i> sp. 1

Hiroaki Tsutsumi, Shigeru Montani, Hiroshi Kobe · Fisheries Science · 2002 · 16 citations · Full text

Natural Sciences, Ecology, Environmental Sciences +14

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

Hayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi et al. · JTO Clinical and Research Reports · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +17